<DOC>
	<DOCNO>NCT01317875</DOCNO>
	<brief_summary>This Phase IB , open-label , dose-finding study JAK 1 2 inhibitor ruxolitinib patient myelofibrosis ( MF ) . The study consist two period : core study period , comprise dose escalation stage safety extension phase Week 24 , extension study period beyond Week 24 3 year , characterize safety efficacy ruxolitinib patient population . The dose escalation phase enroll successive cohort patient receive increase dos ruxolitinib maximum safe start dose ( MSSD ) determine . In safety expansion phase , additional patient treat ruxolitinib MSSD define dose escalation . The primary objective establish MSSD ruxolitinib patient MF start platelet count &lt; 100 x 10 ^9/L</brief_summary>
	<brief_title>Study JAK Inhibitor Ruxolitinib Administered Orally Patients With Primary Myelofibrosis ( PMF ) , Post-Polycythemia Vera-Myelofibrosis ( PPV-MF ) Post-Essential Thrombocythemia-Myelofibrosis ( PET-MF )</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<criteria>Require treatment MF classify least intermediate risk level 1 define International Working Group . Platelet count &lt; 100x10 ^9/L screen Study Day 1 . Received platelet transfusion within 14 day prior Screening evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>